Treatment.com AI - TREIF STOCK NEWS

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announced that Rocket Doctor has been approved as an in-network provider for New York Medicaid, giving 6.9 million beneficiaries (35% of the state's population) access to virtual healthcare services. Starting January 22, 2025, Rocket Doctor's board-certified physicians will offer primary, urgent, and specialty care through their telehealth platform, with accreditation valid until 2030.

Additionally, Rocket Doctor is collaborating with EngageWell, a network of health and human service organizations serving low-income populations in New York City. This partnership, supported by a US$1 million grant, aims to enhance virtual care for aging New Yorkers through telehealth, remote patient monitoring, and addressing social determinants of health.

The initiative is designed to reduce ER visits, decrease wait times, and improve access to timely specialist referrals, particularly for underserved communities who can now receive care from home.

Treatment.com AI has announced the release of its updated Medical Education Suite (MES), coinciding with their participation in the AI Assessment Symposium at the University of Minnesota Medical School. The enhanced MES platform aims to support OSCE exams, taken by 200,000-300,000 medical students globally each year. New features include AI Patient for exam preparation, expanded OSCE Case Packages, and an AI Prep Tool with guided and non-guided learning options. The company plans further developments including AI Doctor in a Pocket and Audio/Video Analysis capabilities through 2024 and early 2025.

Treatment.com AI has launched an updated Medical Education Suite (MES) coinciding with their participation in the AI Assessment Symposium at the University of Minnesota Medical School. The enhanced platform aims to support OSCE exams, taken by 200,000-300,000 medical students globally annually. New features include AI Patient for exam preparation, expanded OSCE Case Packages planned for up to 100 cases through Q4 2024, and an AI Prep Tool with guided and non-guided learning support. Future developments include AI Doctor in a Pocket and Audio/Video Analysis capabilities.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announces its participation in the 2024 Cantech Letter Investment Conference on October 9, 2024 in Toronto, Ontario. CEO Dr. Essam Hamza will deliver an investor presentation at 11:00 AM ET and participate in 1-on-1 meetings with investors. The event will take place at the Arcadian Loft, 8th floor, 401 Bay Street.

Dr. Hamza emphasized the conference's importance, stating, "The healthcare system is at the precipice of substantial modernization and we believe that our proprietary platform can help with reducing its inefficiencies, reducing administration headaches, and ultimately improving patient access and care." Interested parties can contact tara@cantechletter.com to register or schedule 1-on-1 meetings with Treatment.com AI.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided updates on its marketing engagements and focus on AI in medical education. The company has extended its agreement with Leit Media for investor relations services, adding an additional EUR 250,000 for a digital marketing campaign targeting German-speaking investors. Treatment.com has also engaged Interactive Media Group (IMG) for a one-month marketing awareness program for US$23,000.

The company highlighted the global adoption of the Objective Structured Clinical Examination (OSCE) in over 80 countries, with an estimated 200,000-300,000 medical students taking the exam annually. Treatment.com has been providing OSCE services to medical schools, including the University of Minnesota, for the past three years.

Treatment.com will be a lead participant in an upcoming Symposium on AI Assessment in Medical Education. The company is also on track to release two new SaaS solutions in H2 2024: AI Patient and AI Doctor in a Pocket, aimed at supporting medical students and healthcare professionals.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has signed a Collaborative Agreement with SPRYT to explore AI-powered solutions for healthcare challenges. The partnership aims to combine Treatment's Global Library of Medicine (GLM) with SPRYT's AI Medical Office Assistant, Asa, to create an innovative patient onboarding and triaging tool. This collaboration targets reducing administrative costs, which account for 25% ($1 trillion) of annual US healthcare spending, and addressing the $150 billion annual cost of missed appointments.

The partnership aims to improve patient access, reduce healthcare system costs, and streamline processes for healthcare professionals. SPRYT's Asa allows patients to book and manage appointments via messaging apps, while Treatment's GLM provides comprehensive medical history and diagnosis suggestions. The collaboration will focus on developing solutions for markets in the UK, North America, and the Middle East.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has signed a Collaborative Agreement with the University of Edinburgh to utilize Treatment's proprietary Global Library of Medicine (GLM) in the SET4 Systems Engineering initiative. This multi-million dollar project aims to transform long-term care services across the UK, focusing on improving transitions in health and social care for people with Multiple Long-Term Conditions (MLTC).

The collaboration leverages the University of Edinburgh's top-ranking status in industry innovation and infrastructure. The project will initially focus on specific communities in Scotland, with the goal of wider adoption across the UK National Health Service (NHS) and other social care settings. Both parties will also explore additional collaborative and commercial opportunities to enhance healthcare system efficiency and patient care.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) endorses recent recommendations from a Washington roundtable on AI in healthcare. The company's AI-powered Global Library of Medicine (GLM) aims to address key challenges in healthcare, including:

• Alleviating workforce burdens
• Improving efficiency and patient outcomes
• Ensuring equitable access for patients and care teams

The GLM provides high-level clinical support to healthcare professionals, enhancing diagnostic accuracy and transparency. It operates in a secure environment, allowing Large Language Models to query trusted content, reducing risks of misdiagnosis and bias. The platform aims to streamline tasks for healthcare professionals, potentially impacting costs and efficiency for healthcare organizations.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has announced a new AI Pharmacy Assistant solution, set to launch in 2024. This tool aims to support pharmacists in their expanding role in healthcare, particularly in providing clinical decision support services. The AI Pharmacy Assistant is powered by Treatment's proprietary Global Library of Medicine (GLM), offering features such as:

• Automated patient history and symptom recording
• Documentation of patient interactions
• Enhanced diagnostic support
• Error minimization and increased clinical efficiency
• Comprehensive diagnostic information backed by up-to-date medical research

The global clinical decision support systems market is projected to grow from $2.46 billion in 2024 to $4.05 billion by 2029. This new product line represents an additional revenue stream for Treatment.com AI's GLM platform.